Cyrus Bio is an AI-driven discovery company focused on naturally existing proteins that show the potential to be turned into superior therapeutics using AI and deep mutagenesis.

<p>Claim company page to add description</p>


Cyrus Biotechnology

 Designer proteins, created and edited on computers, open up new biotech frontiers 

Cyrus Biotechnology to spin out Levitate Bio for biopharma AI - Pharmaceutical Technology

 Cyrus Biotechnology to Present its Protein Engineering Capability, Immunogenicity Risk Mitigation, and Best-in-Class IgG Protease Candidate at Hit ID Summit 

Cyrus Biotechnology Announces $18M Financing and Acquisition of Orthogonal Biologics to Form an Integrated Software-Driven Pre-Clinical-Stage Drug Discovery Firm - Business Wire

We are excited to discuss our ongoing autoimmune and COVID programs as well as platform collaborations in biologics discovery. We are actively partnering our IdeS enzyme program on an indication by indication basis for certain uses outside of our core acute IgG-mediated autoimmune indications. 

 Designing Proteins to be Molecular Machines 

Photo - Cyrus Biotechnology Announces Potent in vivo Redosability of an Engineered IdeS Protease for IgG-driven Autoimmune Disease, Demonstrating No Anti-drug Antibodies - Business Wire

ADC startup raises €30M; Cyrus Biotechnology to spin out Levitate Bio - Endpoints News

 ADC startup raises €30M; Cyrus Biotechnology to spin out Levitate Bio 

Cyrus Biotechnology reports preclinical data on IgG degrader - BioWorld Online

 Cyrus Biotechnology to Present Its Novel IgG-degrading IdeS Enzyme Development Candidates for Autoimmune ... 

Cyrus Biotechnology to Present Its Novel IgG-degrading IdeS Enzyme Development Candidates for Autoimmune Indications at PepTalk Conference in San Diego - Business Wire

 Cyrus Biotechnology makes acquisition after raising $18M 

 Cyrus Biotechnology Raises $8M Series A Funding To Help Scientists Speed Up Research 


              Cyrus Biotechnology to Present its Protein Engineering Capability, Immunogenicity Risk Mitigation, and Best-in-Class IgG Protease Candidate at Hit ID Summit
            

OpenFold AI Research Consortium Welcomes Three New Members: UCB, NVIDIA and Valence Labs - Business Wire

 Cyrus Biotechnology and the Broad Institute of MIT and Harvard Launch Multi-Target Collaboration to Develop Optimized CRISPR Gene Editing Technology 

Cyrus Biotechnology to Present its Protein Engineering Capability, Immunogenicity Risk Mitigation, and Best-in-Class IgG Protease Candidate at Hit ID Summit - BioSpace

 Cyrus Biotechnology Offers CryoEM Services Based on First-in-class, Peer-reviewed Rosetta Software Methods 


              Home
            

Cyrus Biotech spins out company to expand reach of versatile drug development software - GeekWire

Cyrus is presenting a poster at ASGCT: Come on by, visit with my BD colleagues Andy Jerome and Ramon Salsas Escat, and check out this terrific work.

"A Half-Life Extended IgG Protease with Reduced Immunogenicity to Enable Efficient In Vivo Gene Transfer and Vector Readministration"

Session Date/Time: 5/10/2024 12 - 1:30 PM
Session Title: Friday Posters: Challenges to Immunological Responses to Therapeutic Interventions
Presentation Room: Exhibit Hall
Final Abstract Number: 1793


Cyrus Biotechnology to Present its Protein Engineering Capability, Immunogenicity Risk Mitigation, and Best-in-Class IgG Protease Candidate at Hit ID Summit - Business Wire

Cyrus, the Broad team up to make in vivo CRISPR use safer

 Cyrus Biotech spins out company to expand reach of versatile drug development software 

Seattle startup Cyrus inks protein-design deal with immune biotech Selecta worth up to $1.5 billion - GeekWire

Biotech startups join AWS and other partners in open-source project to help design new proteins - GeekWire

Cyrus Biotechnology Congratulates David Baker, 2024 Nobel Laureate in Chemistry and Cyrus Co-Founder

 New Cyrus Biotechnology Antibody Structure Prediction Software “NextGen” Outperforms Schrödinger and Other Software in Third-Party Test 

 Cyrus Biotechnology Spins out Levitate Bio, a Protein AI, Bioinformatics, and Rosetta Service Provider, to Bring Automated, Customized AI Solutions to Biopharma Drug Discovery 

(Link)

Cyrus Biotechnology and CRISPR pioneers team up to boost gene-editing therapies - GeekWire

 UW spinout takes the legwork out of drug development for biotech companies - Puget Sound Business Journal 

 University of Washington licenses Rosetta protein software to Cyrus Biotech - GeekWire 


              Cyrus Biotech spins out company to expand reach of versatile drug development software
            

AI-fueled protein design startup spun out from Cyrus Biotechnology - BioPharma-Reporter.com

 Cyrus Biotechnology Announces $8M Financing to Expand Computational Drug Discovery Software Platform 


              Cyrus Biotechnology Congratulate Co-Founder David Baker on 2024 Nobel Prize in Chemistry (Business Wire)
            

 For Nobel Prize winner David Baker, it’s back to the lab as protein pioneer helps launch more startups 

Cyrus Biotechnology Announces Potent in vivo Redosability of an Engineered IdeS Protease for IgG-driven Autoimmune Disease, Demonstrating No Anti-drug Antibodies - Yahoo Finance

Cyrus Biotechnology Spins out Levitate Bio, a Protein AI, Bioinformatics, and Rosetta Service Provider, to Bring Automated, Customized AI Solutions to Biopharma Drug Discovery - Business Wire

Biotech Companies Team Up to Design New Proteins with ML - BioSpace

 Cyrus Biotechnology Announces $18M Financing and Acquisition of Orthogonal Biologics to Form an Integrated Software-Driven Pre-Clinical-Stage Drug Discovery Firm 

 Saver Rate Ends Today for Seattle’s Life Science Disruptors 


              Cyrus Biotechnology Announces Potent in vivo Redosability of an Engineered IdeS Protease for IgG-driven Autoimmune Disease, Demonstrating No Anti-drug Antibodies
            

Cyrus Biotechnology Announces Potent in vivo Redosability of an Engineered IdeS Protease for IgG-driven Autoimmune Disease, Demonstrating No Anti-drug Antibodies - The Bakersfield Californian

 Cyrus Biotechnology Announces Release of Antibody Structure Prediction Software for Biologics Drug Development and Discovery 

Cyrus Biotechnology Congratulates David Baker, 2024 Nobel Laureate in Chemistry and Cyrus Co-Founder - Business Wire

Awesome to see our spinout Levitate continuing Cyrus’ original mission of democratizing protein design!

Cyrus Biotechnology Announces Potent in vivo Redosability of an Engineered IdeS Protease for IgG-driven Autoimmune Disease, Demonstrating No Anti-drug Antibodies - Silicon UK

 Cyrus Biotechnology reports preclinical data on IgG degrader 

CyrusBio is attending BIO 2024.
We'll be discussing program partnering and platform access opportunities, so let us know if you'd like to connect there.


Funding news: Cyrus lands $18M and buys startup developing COVID-19 therapeutic; Spare Labs snags $18M for mobility software - GeekWire

Cyrus Biotechnology’s COVID therapeutic lead, ACE2.v2.4, strongly binds and neutralizes SARS-CoV-2 omicron variant potentially providing long term protection - Business Wire

Cyrus Biotechnology

Business:

Drug notes:

About: